In the latest trading session,, 1.15 million United Therapeutics Corp (NASDAQ:UTHR) shares changed hands as the company’s beta touched 0.57. With the company’s most recent per share price at $275.71 changed hands at -$52.69 or -16.04% at last look, the market valuation stands at $12.44B. UTHR’s current price is a discount, trading about -51.54% off its 52-week high of $417.82. The share price had its 52-week low at $266.98, which suggests the last value was 3.17% up since then. When we look at United Therapeutics Corp’s average trading volume, we note the 10-day average is 0.5 million shares, with the 3-month average coming to 472.00K.
Analysts gave the United Therapeutics Corp (UTHR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.75. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended UTHR as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
United Therapeutics Corp (NASDAQ:UTHR) trade information
Instantly UTHR was in red as seen in intraday trades today. With action -14.96%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -21.86%, with the 5-day performance at -14.96% in the red. However, in the 30-day time frame, United Therapeutics Corp (NASDAQ:UTHR) is -8.53% down. Looking at the short shares, we see there were 2.1 million shares sold at short interest cover period of 4.81 days.
The consensus price target for the stock as assigned by Wall Street analysts is 314, meaning bulls need an upside of 12.19% from its recent market value. According to analyst projections, UTHR’s forecast low is 314 with 314 as the target high. To hit the forecast high, the stock’s price needs a -13.89% plunge from its current level, while the stock would need to soar -13.89% for it to hit the projected low.
The 2025 estimates are for United Therapeutics Corp earnings to increase by 13.30%, but the outlook for the next 5-year period is at 6.20% per year.
UTHR Dividends
United Therapeutics Corp is expected to release its next quarterly earnings report on 2025-Apr-29.
United Therapeutics Corp (NASDAQ:UTHR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.82% of United Therapeutics Corp shares while 101.40% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 103.29%. There are 101.40% institutions holding the United Therapeutics Corp stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 12.3176% of the shares, roughly 5.47 million UTHR shares worth $1.74 billion.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.9526% or 4.42 million shares worth $1.41 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were iShares Trust-iShares Core S&P Mid-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 1.45 shares estimated at $401.9 million under it, the former controlled 3.20% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.14% of the shares, roughly 1.41 shares worth around $393.38 million.
